

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement, for which the directors (the “**Directors**”) of Shenzhen Neptunus Interlong Bio-technique Company Limited* (the “**Company**”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement in this announcement or this announcement misleading.*



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People’s Republic of China)
(Stock code: 8329)

TRANSFER OF 9% EQUITY INTERESTS IN JOINT VENTURE COMPANY

Reference is made to the circular and the two announcements issued by the Company on 23 January 2009, 9 June 2009 and 7 August 2009, respectively, in relation to the establishment of 深圳葛蘭素史克海王生物製品有限公司 (Shenzhen GSK-Neptunus Biologicals Co. Ltd.*) (the “**JV Company**”), a joint venture company established by the Company and GlaxoSmithKline Pte Ltd. (“**GSK Pte**”). Unless otherwise specified herein, the terms used in this announcement shall have the same meanings as defined in the above documents.

Pursuant to the Executed JV Contract, upon the first anniversary of the date of establishment of the JV Company, GSK should purchase and the Company should sell a portion of the JV Company’s Equity Interests, which should account for 9% of the Registered Capital, at a consideration equal to 150% of the original value of such Equity Interests. The first anniversary of the date of establishment of the JV Company was on 6 August 2010.

The Board is pleased to announce that the Company has sold and GSK Pte has purchased 9% Equity Interests of the JV Company pursuant to the Executed JV Contract at a consideration of US\$10,574,550 (which was equivalent to 150% of the original value of the 9% Equity Interests) (the “**Consideration**”), and the JV Company has obtained the new Enterprise Legal Person Business License issued by the Market Supervision Administration of Shenzhen Municipality in connection with such equity transfer on 12 August 2010. The Company and GSK Pte has applied to the Shenzhen branch of the State Administration of Foreign Exchange of the PRC for the remittance of the Consideration to the Company. Upon the completion of such application procedures, the Company will receive the Consideration in its bank account in the PRC.

As a result of the transfer of the 9% Equity Interests, as at the date of this announcement, the JV Company is held as to 51% by the Company and 49% by GSK Pte.

By order of the Board
**Shenzhen Neptunus Interlong
Bio-technique Company Limited***
Zhang Si Min
Chairman

Shenzhen, the PRC, 17 August 2010

As at the date of this announcement, the executive Directors are Mr. Zhang Si Min and Mr. Chai Xiang Dong; the non-executive Directors are Mr. Ren De Quan and Ms. Yu Lin; and the independent non-executive Directors are Mr. Lu Sun, Mr. Yick Wing Fat, Simon and Mr. Poon Ka Yeung.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “latest company announcement” page for at least 7 days from the day of its posting and on the Company’s website at www.interlong.com.

** For identification purposes only*